Evolocumab (PCSK9 inhibitor) versus placebo; overall primary-endpoint hazard ratio 0.85.
Possible enrichment: recruit broadly → select subgroup → concentrate recruitment.
Results redrawn: Sabatine et al. (2017), Evolocumab and Clinical Outcomes…; Marston et al. (2020), Predicting Benefit From Evolocumab Therapy…, Fig. 2, corrected 2024.
Freidling, Zhao, Gao (2026), Selective Randomization Inference for Adaptive Experiments.
Nominal one-sided level: 5% · Probabilities calculated by numerical integration.
| Rejection probability (%) | Pooled \(z\) | Bonferroni– Bonferroni |
Stage 2 \(z\) only | Selective \(z\) |
|---|---|---|---|---|
| Effects \((0,0,0,0,0)\) | ||||
| Marginal false rejection | 16.6 | 4.9 | 5.0 | 5.0 |
| Effects \((0.3,0,0,0,0)\) | ||||
| Marginal false rejection | 5.2 | 2.0 | 0.9 | 0.9 |
| False rejection given \(S\in\{2,3,4,5\}\) | 28.2 | 10.6 | 5.0 | 5.0 |
| Power given \(S=1\) | 95.3 | 73.7 | 68.3 | 69.7 |
| Effects \((0.3,-0.3,-0.3,-0.3,-0.3)\) | ||||
| Power given \(S=1\) | 91.5 | 70.6 | 68.3 | 88.5 |

Freidling, Zhao and Gao (2026), Selective Randomization Inference for Adaptive Experiments, Fig. 3, p. 9. CC BY 4.0; cropped from the original.
Families in 108 schools.
Heppen, Kurki and Brown (2020), Can Texting Parents Improve Attendance in Elementary School?, pp. 3–4, Exhibit 5. Design redrawn.
The same family receives successive interventions. A possible causal structure:
\(Y_1\) is post-treatment for \(A_1\), but pre-treatment for \(A_2\).
Design: Heppen, Kurki and Brown (2020), report. Causal diagram: teaching schematic. Further reading: Hernán and Robins, Causal Inference: What If, chs. 19–21.

Heredity and environment (1920)


Wright (1920), The Relative Importance of Heredity and Environment in Determining the Piebald Pattern of Guinea-Pigs, Figs. 5–6, pp. 328–329; public domain. Portrait (1965): UW–Madison Archives, © UW System Board of Regents; educational use permitted.